Dr. Wang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
807 Farson St
Ste 210
Belpre, OH 45714Phone+1 740-376-5000Fax+1 740-376-5002
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2003 - 2005
University of Oklahoma School of Community Medicine (Tulsa)Residency, Internal Medicine, 1999 - 2002
Fourth Military Medical University Class of 1984
Certifications & Licensure
OH State Medical License 2005 - 2026
MT State Medical License 2021 - 2025
MO State Medical License 2007 - 2021
UT State Medical License 1997 - 2006
OK State Medical License 2001 - 2005- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 38 citationsTIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.Vivian Changying Jiang, Dapeng Hao, Preetesh Jain, Yijing Li, Qingsong Cai
Molecular Cancer. 2022-09-26 - 72 citationsDurable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas
Leukemia. 2019-09-26 - 3 citationsFinal results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those w...Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy
Haematologica. 2024-01-01
Abstracts/Posters
- Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Lan...Michael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell LymphomaMichael L. Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...Michael Wang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND ...ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Dual Inhibition of PI3K Signaling and Histone Deacetylation Halts Proliferation and Induces Lethality in Mantle Cell Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Longest Follow-up of CAR T-cell Therapy in Mantle Cell Lymphoma Points Out to Long-Term Responses with Manageable Safety in Patients with Relapsed/Refractory DiseaseJune 14th, 2022- Rucaparib Is Effective in Maintenance Treatment for Ovarian CancerJune 8th, 2022
- What to Know About Mantle Cell LymphomaSeptember 28th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
